Effect of selected catechins on doxorubicin antiproliferative efficacy and hepatotoxicity in vitro by PETRA RUDOLFOVÁ et al.
The anthracycline antibiotic doxorubicin (DOX) is one of the most useful anticancer
agents and is still a cornerstone in the therapy of many carcinoma types. Unfortunately,
DOX therapy is mostly accompanied by severe side effects based on its systemic toxicity,
especially cardiotoxicity (1–3). DOX hepatotoxicity, sometimes passing into liver cirrhos-
is, has been also reported (4, 5).
Oxidative damage mediated by generation of reactive oxygen species (ROS), name-
ly, induction of hydroxyl radicals formation, is most likely the mechanism of DOX anti-
tumor activity (3, 6, 7). Quinone-containing DOX is enzymatically activated through
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Catechins may influence both desirable and undesirable
effects of many drugs. In this study, the in vitro effect of
(+)-catechin, (–)-epicatechin, (–)-epigallocatechin, (–)-epica-
techin gallate, and (–)-epigallocatechin gallate (EGCG) on
the efficacy of anticancer drug doxorubicin (DOX) was
studied in HCT-8 cancer cells. Rat hepatocytes were used
to study the influence of EGCG on DOX hepatotoxicity.
Cell proliferation and viability were studied by 3-[4,5-di-
methylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide and
neutral red uptake test assays. Formation of reactive
oxygen species (ROS) was determined using the dichlo-
rofluorescein assay. All of the studied catechins (1–25
µmol L–1) had no effect on the proliferation of intestinal
cancer cells and did not affect the antiproliferative effect
of DOX (1–8 µmol L–1) in these cells. Moreover, EGCG at
25 µmol L–1 increased the viability of isolated hepatocytes
and significantly protected these cells against DOX-in-
duced toxicity and ROS production. Consumption of
EGCG during DOX therapy seems to be safe and bene-
ficial, since EGCG does not decrease DOX anticancer ef-
ficacy and could ameliorate DOX hepatotoxicity.
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one-electron reduction, by NADPH-cytochrome P450 reductase or NADH-dehydrogen-
ase, to free radical intermediates, with subsequent production of reactive oxygen species
in the presence of molecular oxygen. DOX also acts as a powerful iron chelator and the
resulting DOX-Fe2+ complex is an efficient catalyst of the hydrogen peroxide conversion
to the hydroxyl radical (8). It has been proposed that especially hydroxyl radicals may
react with unsaturated lipids initiating lipid peroxidation, with cellular DNA inducing
DNA damage, and oxidize certain functional proteins. Nevertheless, DOX treatment can
also place non-cancerous tissues under conditions of oxidative stress and thereby impair
the health of organs such as heart, liver, kidney, and brain. Such damage not only limits
the effective dosage of DOX but also deteriorates the quality of life of cancer patients
after chemotherapy (9, 10). Therefore, an antioxidant co-administered with cytostatics
may actually reduce the severity of the adverse effects of chemotherapy. In order to eli-
minate DOX-mediated oxidative stress, addition of certain antioxidants to DOX therapy
has been intensively studied. Many studies have focused on natural antioxidant com-
pounds, like polyphenols (reviewed, e.g., in refs. 11, 12). On the other hand, antioxidants
might also reduce ROS created by cytostatics in cancer cells, and thereby interfere with
the drug’s antineoplastic activity (13, 14). With respect to both points of view, concurrent
administration of antioxidants with DOX is questionable and further studies are neces-
sary.
Polyphenolic compounds, ubiquitously found in fruits and vegetables, exhibit mul-
tiple biological effects, including antiviral, antibacterial, anti-inflammatory, vasodilatory,
antioxidant, and antiradical activities (15). They also exert chemopreventive effects and
could be used for attenuation of the side effects of cytostatics, including DOX (11).
Among the polyphenols tested, catechins showed a great potential of preventing
DOX-mediated toxicity. Catechins, the main polyphenolic compounds of green tea, are
considered to be very beneficial for the human organism owing to their anticancer, anti-
bacterial, antiviral, antioxidant, and antiradical properties. The ability of catechins to at-
tenuate DOX toxicity was frequently described. In rat, individual catechins and/or green
tea extract exhibited protective effects against DOX-induced cardiovascular abnormali-
ties (16), cardiomyocyte injury (17, 18), brain toxicity (19), and spermatogenic disorders
(20). Moreover, catechins are able to inhibit carbonyl reductase 1, the main DOX deac-
tivation enzyme (21), and in this way they enhanced DOX efficacy in tumor-bearing
mice (22). On the other hand, antioxidant properties of catechins could decrease DOX-
-mediated oxidative stress in cancer cells, which is believed to contribute to DOX anti-
proliferative effect (8, 12). Owing to this fact, the risk of the possible decrease of DOX
anticancer efficacy by catechins should be also kept in mind.
Nowadays, the use of antioxidants in combination with chemotherapeutic agents is
an important issue in cancer treatment and it has been the subject of extensive recent
debates. The mechanism of hepatoprotective activity of green tea catechins in the model
of DOX-induced toxicity in non-cancerous tissues has not been elucidated yet. There-
fore, the present study was designed to evaluate the in vitro effects of several catechins
(namely, (+)-catechin, (–)-epicatechin, (–)-epigallocatechin, (–)-epicatechin gallate and
(–)-epigallocatechin gallate), representing the most abundant flavonoids in green tea, on
the efficacy and toxicity of DOX. For this purpose, the intestinal tumor cell line HCT-8
and primary culture of isolated rat hepatocytes were used as model systems.
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(+)-Catechin, (–)-epicatechin, (–)-epigallocatechin, (–)-epicatechingallate and (–)-epigal-
locatechin gallate (EGCG), RPMI-1640 medium, Ham-F12 medium, William´s E medium,
N-2-hydroxyethylpiperazine-N´-2-ethanesulfonic acid (HEPES) buffer, ethylene glycol-
-bis(aminoethylether)-N,N,N´,N´-tetraacetic acid (EGTA), 2´,7´-dichlorodihydrofluorescein
diacetate, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT), neutral red,
and collagenase from Clostridium histolyticum were supplied by Sigma-Aldrich (Czech
Republic). Fetal bovine serum (FBS), horse serum (HS), and gentamicin sulfate were pur-
chased from Invitrogen (USA) and bovine serum albumin (BSA) from Fluka (Czech Re-
public). Doxorubicin was provided by Pharmacia & Upjohn (Italy). All other chemicals
were of HPLC or analytical grade.
Stock solutions were prepared in dimethylsulfoxide (DMSO) and stored at 4 °C in
the dark.
Cancer cell culture
Human colorectal adenocarcinoma cell line HCT-8 was purchased from ATCC (Ame-
rican Type Culture Collection, USA). Cells were multiplied in three passages, frozen in
aliquots and stored in liquid nitrogen. The absence of mycoplasma in all cell lines used
in the laboratory was periodically checked by Generi Biotech (Czech Republic). For eve-
ry set of experiments (lasting 3–9 weeks), new storage cells were resuscitated. The hu-
man colorectal adenocarcinoma cell line HCT-8 was maintained in RPMI-1640 medium
supplemented with 5 % heat-inactivated FBS, 5 % heat-inactivated HS, 1 % Na-pyruvate
and 0.5 % penicillin/streptomycin. Cells were grown in T-75 cm2 culture flasks in a hu-
midified atmosphere containing 5 % CO2 at 37 °C.
Preparation of primary culture of rat hepatocytes
Male Wistar rats were obtained from MediTox (Czech Republic). They were housed
in air-conditioned animal quarters with a 12 h light/dark cycle. Food (a standard rat
chow diet) and water were provided ad libitum. The rats were cared for and used in ac-
cordance with the Guide for the Care and Use of Laboratory Animals and all animal ex-
perimental procedures were approwed by the Ethical Committee of Charles University
(Prague, Czech Republic). Animals were anesthetized with ether, sacrificed by decapi-
tation, liver tissues were removed immediately and hepatocytes were prepared by the
two-step collagenase method (23). Briefly, liver was perfused with salt solution [140 mmol
L–1 NaCl, 5 mmol L–1 KCl, 0.8 mmol L–1 MgSO4 in Na+/K+ phosphate buffer (0.2 mmol
L–1, pH 7.4) containing a calcium binding component (0.4 mmol L–1 EGTA)]. Consequ-
ently, the liver was perfused with phosphate buffer containing calcium chloride (1.46
mmol L–1) and collagenase (30 mg per 100 mL) at 37 °C. Collagenase perfusion proce-
eded for 5–6 min. After perfusion, the liver was transferred to the medium containing
BSA and the hepatocytes were released. The obtained suspension was filtered through a
nylon mesh and centrifuged at 40xg for 5 min at 4 °C. The pellet was re-suspended in
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chilled buffer and the washing procedure was repeated twice. Finally, three million viab-
le cells (75–80 %) in 3 mL of culture medium ISOM (1:1 mixture of Ham F12 and Wil-
liams’ E) were placed into 96-well plates. The FBS was added to the culture medium (10 %).
Cultures were maintained without the tested compounds for 4 hours at 37 °C in a humid
atmosphere of air and 5 % CO2.
Cell viability tests
Catechins were dissolved in DMSO to obtain stock solutions with concentrations of
1, 5, 10 and 25 mmol L–1. In order to prepare samples with final concentrations of 1, 5, 10
and 25 µmol L–1, these stock solutions were diluted 1000-times with an appropriate cell
culture medium (ISOM or RPMI-1640). Hence, the final concentration of DMSO in all
samples was 0.1 %. The hepatocytes or HCT-8 cancer cells cultured in the appropriate
medium with 0.1 % DMSO only were used as control samples in all the tests described
below.
Proliferation of cancer cells was assayed using the neutral red uptake test (NRU)
after 24- and 48-h exposures. The viability of hepatocytes was tested using the MTT
assay after 24-h exposure and was monitored microscopically.
NRU test. – NRU test represents the simplest and cheapest method for detection of
cell viability/proliferation. The cells were cultured in 96-well plates in the RPMI-1640
medium supplemented with 5 % heat-inactivated FBS, 5 % heat-inactivated HS, 1 % Na-
-pyruvate and 0.5 % penicillin/streptomycin with individual catechins (concentrations
1–25 µmol L–1), with DOX alone (concentrations 1–8 µmol L–1) and with combinations of
DOX (concentrations 1–8 µmol L–1) + catechins (fixed concentration 5 µmol L–1). After
24- and 48-h exposure intervals, the medium was removed and 100 µL of neutral red-
-containing medium was added into each well. Plates were incubated for additional 3h
at 37 °C. Cells were then washed with 100 µL of PBS. Cells were fixed in a solution of 0.5 %
formaldehyde/1 % calcium chloride for 15 min. The neutral red dye was extracted from
viable cells with the solvent (50 % ethanol/1 % acetic acid) by shaking for 30 min at
room temperature. The absorbance of solubilized dye was measured using an Infinite
M200 spectrophotometer (Tecan, Switzerland) at 540 nm. Each sample was assayed in
six parallels and three independent experiments were performed. Viabilities of treated
cells were expressed as percentage of untreated control (100 %).
MTT assay. – For cells with weaker attachment to the plastic bottom (i.e., isolated
hepatocytes), the MTT assay is preferred to the NRU test as the washing steps are not
required in the MTT assay. Hepatocytes were cultured in 96-well plates in the medium
with epigallocatechin gallate at concentrations of 5–25 µmol L–1. After exposure, 25 µL
of MTT solution (3 mg of MTT in 1 mL of phosphate buffered saline, pH 7.4) was added
to each well. Final MTT concentration in all wells was 1.8 mmol L–1. Plates were incu-
bated for additional 2 h at 37 °C, then the medium was removed and the formed for-
mazan was dissolved in 50 µL of 80 mmol L–1 HCl in isopropanol by 30-min shaking.
The absorbance in each well was quantified by measuring at 570 nm, with background
correction at 690 nm. Cell-free blank samples containing EGCG in the medium only were
incubated with MTT. Since no changes in the absorbance corresponding to MTT were
observed, it can be concluded that EGCG did not cause reduction of MTT to formazan in
this experimental setup.
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Microscopic monitoring. – Hepatocytes were cultured in 96-well plates in the medium
with DOX alone (concentrations 10 and 25 µmol L–1) and with combinations of DOX
(concentrations 10 and 25 µmol L–1) + EGCG (fixed concentration 5 µmol L–1). During
24-h exposure, the morphology of cells was monitored and documented using a Nicon
Eclipse TS100 inverted microscope, 10x Nikon air objective, digital cool camera 1300Q
(VDS Vosskühler, Germany) and software NIS-Elements AR 2.20 (Laboratory Imaging,
Prague, Czech Republic).
Determination of cellular reactive oxygen species (ROS) formation
To assess ROS generation in hepatocytes, measurement of 2’,7’-dichlorodihydro-
fluorescein-diacetate (H2DCF-DA) oxidation was used. This non-fluorescent reagent dif-
fuses passively through the plasma membrane into the cell, where acetate groups are
cleaved by intracellular esterases. The compound can then be oxidized by ROS formed
within the cell (particularly by hydroxyl radicals, OH) to form fluorescent dichloro-
fluorescein, while the fluorescence intensity is proportional to the ROS level (24).
Isolated hepatocytes seeded in a 96-well plate at a density of 2,500 cells per well were
washed with PBS buffer and loaded with 100 µL of 5 µmol L–1 H2DCF-DA and 100 µL of
PBS buffer with DOX alone (concentrations 10 and 25 µmol L–1) and with combinations
of DOX (10 and 25 µmol L–1) + EGCG (5, 10 and 25 µmol L–1). After 12 h of incubation,
fluorescence intensity was measured for 60 min at 37 °C using a microplate reader (Tec-
an Infinite M200) at lex = 485 nm and lem = 525 nm. The 3 % H2O2 solution was used as
a positive control.
Statistical analysis
All calculations were done using Microsoft Excel and GraphPad Prism 6.02 (Graph-
Pad Software, USA). Statistical significance was tested by one-way ANOVA and differ-
ences were considered statistically significant when p < 0.05.
RESULTS AND DISCUSSION
Antiproliferative effect of catechins in HCT-8 cells
The results showed no effect of the (+)-catechin, (–)-epicatechin, (–)-epigallocate-
chin, (–)-epicatechingallate and (–)-epigallocatechin gallate on the viability of HCT-8
cells (Fig. 1). Even the highest concentration of studied catechins (25 µmol L–1) did not
significantly decrease proliferation of these cancer cells.
In contrast to our results, an antiproliferative effect of certain catechins on cancer
cells was reported. Seeram et al. (25) observed pronounced inhibition of proliferation of
MCF-7 (breast), HCT-116 (colon) and NCI-H460 (lung) cancer cells caused by galloylated
catechins, such as (–)-gallocatechin gallate, (–)-EGCG and (–)-gallocatechin. The (–)-gal-
locatechin gallate 50 µmol L–1 inhibited proliferation of MCF-7, HCT-116 and NCI-H460
cells by 97, 93 and 67 %, respectively. EGCG 50 µmol L–1 was the most effective studied
flavonoid, with 100 % inhibition of MCF-7 cells proliferation (25). Liang et al. (26) report-
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ed the antiproliferative effect of epicatechin gallate (ECG) and EGCG in hepatocellular
carcinoma cells BEL-7404, with the IC50 values of 1148 and 567 µmol L–1 for ECG and
EGCG, respectively. This discrepancy could be explained by the differences in the cell
line used and mainly by different concentrations. Much higher concentrations were used
than in our experiments when the catechin concentrations ranged between 1 and 25
µmol L–1, in the studies mentioned above. Systemic bioavailability of catechins after oral
administration is low due to their poor absorption (27). For example, Chow et al. (28)
reported maximal plasma concentration of EGCG of 1.7 µmol L–1, after a single-dose
oral administration of one tablet of Polyphenon E (a green tea extract containing 400 mg
of EGCG) to healthy human volunteers. On the other hand, exposure of intestinal and
colonic mucosa to these compounds is high (27).
Effect of catechins on antiproliferative activity of DOX in HCT-8 cells
DOX alone significantly inhibited cell proliferation in a concentration-dependent
manner. The addition of catechins to DOX had no effect on cell viability. None of the
studied catechins influenced the antiproliferative effect of DOX in the cancer cell line
HCT-8 (Fig. 2).
Liang et al. (26) described the ability of ECG and EGCG to augment antitumor acti-
vity of DOX in the hepatocellular carcinoma cell line BEL-7404 as well as in murine xeno-
grafts. However, in these experiments very high concentrations of catechins (0.15–2.5 mmol
L–1), were used, which highly exceeded common plasmatic concentrations of these com-
pounds. Stammler and Volm (29) showed a sensitizing effect of EGCG and EGC on the
doxorubicin-resistant colon cancer cell line (SW620-dox) and murine sarcoma (S180-dox).
In contrast, in our experiments, catechins in 5 µmol L–1 concentrations did not affect DOX
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Fig. 1. The effect of catechin (C), epicatechin (EC), epigallocatechin (EGC), epicatechin 3-gallate (ECG),
and epigallocatechin gallate (EGCG) in concentrations of 1, 5, 10, and 25 µmol L–1 on the prolife-
ration of cancer cells HCT-8. The exposition lasted 48 h. The data are expressed as percentage of the
control cells number (cells exposed to vehicle 100 %) ± SD (n = 6).
antiproliferative efficacy in intestinal cancer cells. Addition of catechins caused no poten-
tiation but also no decrease of DOX efficacy in these cancer cells. This finding indicates that
concomitant consumption of low doses of catechins does not influence DOX therapy.
Effect of EGCG on the viability of isolated hepatocytes and on DOX-induced
toxicity in hepatocytes
The potential health benefits associated with green tea consumption have been par-
tially attributed to the antioxidative properties of polyphenols, particularly to catechins,
among which EGCG is the most effective (30). Therefore, the effect of EGCG on DOX
toxicity in non-cancerous cells was followed up. For this purpose, the primary culture of
isolated hepatocytes was used. When the effect of EGCG (24-h exposure) on the viability
of hepatocytes was tested, a mild increase (p < 0.01) in their viability was found only
with the highest EGCG concentration (25 µmol L–1),while lower concentrations of EGCG
had no effect (Fig. 3). When hepatocytes were exposed for 24-h to DOX (10 and 25 µmol
L–1), a pronounced destruction of cells was observed. However, when hepatocytes were
exposed to combinations of DOX (10 and 25 µmol L–1) with 5 µmol L–1 EGCG, no da-
mage occurred after 24-h exposure (Fig. 4). Protective effect of EGCG may depend on its
ability to inhibit carbonyl reductase 1, the enzyme responsible for the formation of a more
toxic DOX metabolite (21), and also on EGCG antioxidant and antiradical properties.
Hepatoprotective effect of catechin (200 mg per kg per week) in DOX-treated (5 mg
per kg per week) rats was described by Kalendar et al. (5). Malondialdehyde level, glu-
tathione peroxidase and catalase activities were significantly decreased in the catechin+
DOX-treated group compared to the DOX-treated group (5). These observations together
with our results indicate that catechins could reduce DOX-induced hepatotoxicity.
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Fig. 2. The effect of catechin (C), epicatechin (EC), epigallocatechin (EGC), epicatechin 3-gallate (ECG),
and epigallocatechin gallate (EGCG) in concentration of 5 µmol L–1 on DOX concentration-depend-
ent antiproliferative efficacy in cancer cells HCT-8. The exposition lasted 48 h. The data are expres-
sed as percentage of the control cells number (cells exposed to vehicle 100 %) ± SD (n = 6).
Effect of EGCG on the DOX-induced formation of ROS in hepatocytes
To verify the antioxidant/antiradical mechanism of EGCG protective activity against
DOX-mediated hepatotoxicity, the ROS-scavenging ability of EGCG in rat hepatocytes
exposed to DOX was studied by the dichlorofluorescein assay. The results (Fig. 5) prov-
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Fig. 3. The effect of epigallocatechin gallate (EGCG) at concentrations of 5, 10 and 25 µmol L–1 on
the viability of isolated hepatocytes. The exposure lasted 24 h. The data are expressed as percentage
of the control cells (cells exposed to vehicle 100 %) ± SD (n = 6). The viability of control cells repre-
sents 100 %. Asterisk indicates a significant difference from the control (p < 0.01).
Fig. 4. Microscopic photo-documentation of the primary culture of isolated rat hepatocytes: a) with-
out treatment, b) vehicle-treated, c) treated with 10 µmol L–1 DOX, d) treated with 10 µmol L–1 DOX
+ 5 µmol L–1 EGCG, e) treated with 25 µmol L–1 DOX, f) treated with 25 µmol L–1 DOX + 5 µmol L–1
EGCG, for 24 h.
ed that DOX (10 and 25 µmol L–1) markedly induced ROS formation in a concentration-
-dependent manner (p < 0.01). In control hepatocytes (without DOX), EGCG 25 µmol L–1
did not significantly decrease the basal formation of ROS, but it restricted ROS forma-
tion in hepatocytes exposed to DOX at 10 and 25 µmol L–1 by 84.0 and 86.4 % (p < 0.01),
respectively. Even the lowest EGCG concentration (5 µmol L–1) decreased the DOX-in-
duced ROS formation up to 75.6 or 89.5 % in hepatocytes (DOX concentrations of 10 and
25 µmol L–1, respectively).
Zheng et al. (18) reported protective action of EGCG against the DOX-induced ROS
formation in cardiomyocytes. However, higher EGCG concentration (25 µmol L–1) was
necessary for a marked decrease of ROS formation in these cells (18).
CONCLUSIONS
Catechins had no influence on the proliferation of HCT-8 cancer cells and on the
viability of isolated rat hepatocytes. Further, they did not interfere with the antiproli-
ferative activity of DOX in the HCT-8 cancer cells. On the other hand, EGCG signific-
antly protected rat hepatocytes against DOX-induced toxicity (at all tested concentrati-
ons), which was mainly caused by the formation of ROS. The protective effect of EGCG
was probably caused by its antioxidant/antiradical properties. Taking together, consump-
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Fig. 5. Formation of ROS in hepatocytes exposed to epigallocatechin gallate (EGCG) in concentra-
tions of 5, 10 and 25 µmol L–1, to DOX in concentrations of 10 and 25 µmol L–1, and to DOX + EGCG
combinations. The exposition lasted 12 h. The 3 % H2O2 solution was used as a positive control. The
data (relative fluorescence units) represent the mean ± SD (n = 6). Asterisk indicates a significant
difference from DOX-treated cells (p < 0.01).
tion of dietary supplements containing catechins, such as green tea, during chemothe-
rapy with DOX, seems to be safe and beneficial, since catechins do not decrease anti-
cancer efficacy of DOX but could attenuate DOX hepatotoxicity. However, the in vivo
experiments (including animal models) should be performed for confirmation of the ob-
tained results.
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